2023 World Conference on Lung Cancer (Posters)-P1.27. NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma

P1.27. NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma - PDF(Abstract)

Back to course

Pdf Summary

The study titled "NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma" evaluates the safety and efficacy of neoadjuvant icotinib plus chemotherapy in patients with resectable stage II-IIIB EGFR-mutant non-small cell lung cancer (NSCLC). Neoadjuvant treatment is increasingly used to downstage tumors before surgery and improve clinical outcomes.<br /><br />The study is an ongoing, single-arm, phase II trial. Eligible patients had resectable stage II-IIIB EGFR-mutant lung adenocarcinoma and received 8 weeks of oral icotinib plus 2 cycles of chemotherapy, followed by surgical resection. The primary endpoint was major pathological response, and secondary endpoints included R0 resection rate, objective response rate, disease control rate, disease-free survival, overall survival, and safety.<br /><br />Out of 47 screened patients, 30 were enrolled and received neoadjuvant therapy. Among them, 27 completed at least 8 weeks of therapy and 26 underwent surgical resection without surgical delays. Successful R0 resection was achieved in 96.2% of pathologically evaluable patients, and a major pathological response was observed in one patient. The majority of patients had an objective response and disease control during neoadjuvant therapy. Treatment-related adverse events were reported in 83.3% of patients, with most being low-grade.<br /><br />The study concludes that neoadjuvant icotinib plus chemotherapy is an effective and feasible treatment for resectable stage II-IIIB EGFR-mutant NSCLC. Final results are still pending, and further analysis regarding changes in plasma EGFR mutation copy numbers and potential resistance-associated genes is awaited. The study will provide more comprehensive findings in the future.<br /><br />Keywords for this study include lung cancer, neoadjuvant therapy, and EGFR tyrosine kinase inhibitors. This study falls under the track of early-stage non-small cell lung cancer at the World Conference on Lung Cancer 2023.

Asset Subtitle

Fang-Liang Lu

Meta Tag

Speaker Fang-Liang Lu

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

NEOIPOWER

icotinib plus chemotherapy

neoadjuvant treatment

resectable stage II-IIIB

EGFR-mutant lung adenocarcinoma

non-small cell lung cancer

NSCLC

surgical resection

major pathological response

R0 resection rate